Understand · Treat · Recover

Chemoradiotherapy and Multimodality Treatment

Radiation treats a defined area, while chemotherapy can enhance its effect and treat disease beyond that area.

For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.

This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.

Chapter 11 of 20

The CROSS approach

CROSS-based neoadjuvant chemoradiotherapy combines weekly carboplatin and paclitaxel with radiation, traditionally 41.4 Gy over 23 fractions, followed by surgery in suitable esophageal/GEJ cancers. It is not a universal regimen for every stomach tumour. Histology, the tumour’s centre, extension up the esophagus and the planned operation influence whether it is appropriate.

How newer evidence changes the discussion

ESOPEC compared perioperative FLOT with CROSS-based treatment in resectable esophageal adenocarcinoma and favoured FLOT for overall survival. This has strengthened the role of perioperative FLOT in fit patients with adenocarcinoma. It does not make radiation obsolete, and it should not be extrapolated unchanged to esophageal squamous cell carcinoma. The surgical and oncology team should explain why one pathway fits a particular GEJ tumour.

Gastric versus junctional treatment

For a gastric primary, perioperative systemic therapy or surgery followed by adjuvant chemotherapy are common strategies, depending on stage and region. Routine addition of radiation after an adequate R0 resection and appropriate systemic treatment is not necessary for everyone. Positive margins or inadequate nodal surgery may prompt selected postoperative chemoradiotherapy discussions. Previous radiation and surgical anatomy matter.

Planning and side effects

Radiation planning uses a CT simulation, positioning and a defined target while limiting exposure to heart, lungs, liver, kidneys and bowel. Treatments are usually delivered on weekdays. Fatigue, nausea, reduced appetite, swallowing discomfort and low counts can occur. Dietetic support and hydration should start early. Fever, inability to drink, bleeding or new breathlessness need prompt contact rather than waiting for the next appointment.

When surgery is not possible

Definitive chemoradiotherapy can be appropriate for selected esophageal/GEJ cancers when surgery is unsuitable, with intent and follow-up clearly explained. Radiation can also relieve bleeding, pain or obstruction in advanced disease. A short symptom-control course has a different purpose and dose plan from curative chemoradiotherapy. Ask which goal applies and how response will be assessed.

Key takeaways

Use the tumour’s location, histology and contemporary comparative evidence to choose a combined-treatment pathway.

Frequently asked questions

Does every GEJ cancer need radiation?

No. Perioperative systemic therapy is often appropriate for adenocarcinoma.

Is CROSS used for all gastric cancers?

No. It belongs primarily to selected esophageal/GEJ pathways.

Will external-beam radiation make me radioactive?

No. Standard external-beam treatment does not make a person radioactive.

Can radiation help bleeding?

Yes, in selected patients, alongside other measures such as endoscopy.

Does ESOPEC apply to squamous cancer?

It studied adenocarcinoma; squamous disease needs its own evidence.

Can surgery follow chemoradiation?

Yes, when it is the planned neoadjuvant pathway and the patient remains suitable.

References and further reading